SUMMARY Increasing evidence suggests that Parkinson’s disease is an autoimmune disorder, with findings of elevated peripheral blood mononuclear cell in patients, and antigenic properties of α-synuclein driving both the innate and adaptive immunity. Yet, how the interaction of α-synuclein and a specific immune response participates to Parkinson’s disease ontogenesis has remained unanswered. Here, we reveal that autoimmune response to an α-synuclein antigen underlies Parkinson’s disease. We demonstrate that autoimmunity mediated by CD4+T cell activation with α-synuclein α-syn 61-75 antigen is required to lead to immune cell infiltration and localized inflammation in the substantia nigra, triggering dopaminergic cell neurodegeneration and deficits in locomotion and gait kinematics. This study offers the first immune-induced mouse model that recapitulates all features of Parkinson’s disease to study the mechanisms triggering disease onset. It provides the basis for temporally tracking symptom development, exploring preventive strategies and prodromal therapeutic interventions in Parkinson’s Disease. In brief Peripheral α-synuclein immunization causes Parkinson’s disease-like symptoms in mice. Highlights - Both CD4+ T cells and α-synuclein are essential for Parkinson’s disease ontogenesis. - Peripheral injection of α-syn 61-75 induces significant CD4+ T cell infiltration in the mouse brain. - α-syn 61-75 immunization is associated with inflammation, α-synuclein aggregation and dopaminergic cell loss in the substantia nigra pars compacta. - Levodopa-sensitive motor symptoms are detected 8 weeks following α-syn 61-75 immunization in mice. - This study offers a novel autoimmune α-synuclein induced mouse model of Parkinson’s disease.
No takes yet. Share an insight, caveat, or question.
Parkinson et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: